GB9622981D0 - Cystic fibrosis medicaments - Google Patents

Cystic fibrosis medicaments

Info

Publication number
GB9622981D0
GB9622981D0 GBGB9622981.0A GB9622981A GB9622981D0 GB 9622981 D0 GB9622981 D0 GB 9622981D0 GB 9622981 A GB9622981 A GB 9622981A GB 9622981 D0 GB9622981 D0 GB 9622981D0
Authority
GB
United Kingdom
Prior art keywords
medicaments
cystic fibrosis
cystic
fibrosis
fibrosis medicaments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB9622981.0A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Wales College of Medicine
Original Assignee
University of Wales College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Wales College of Medicine filed Critical University of Wales College of Medicine
Priority to GBGB9622981.0A priority Critical patent/GB9622981D0/en
Publication of GB9622981D0 publication Critical patent/GB9622981D0/en
Priority to PCT/GB1997/003036 priority patent/WO1998019679A1/en
Priority to CA002270355A priority patent/CA2270355A1/en
Priority to AU48751/97A priority patent/AU4875197A/en
Priority to EP97911336A priority patent/EP0973521A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
GBGB9622981.0A 1996-11-05 1996-11-05 Cystic fibrosis medicaments Pending GB9622981D0 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GBGB9622981.0A GB9622981D0 (en) 1996-11-05 1996-11-05 Cystic fibrosis medicaments
PCT/GB1997/003036 WO1998019679A1 (en) 1996-11-05 1997-11-05 Cyclopentylxanthine derivatives for use in the treatment of cystic fibrosis
CA002270355A CA2270355A1 (en) 1996-11-05 1997-11-05 Cyclopentylxanthine derivatives for use in the treatment of cystic fibrosis
AU48751/97A AU4875197A (en) 1996-11-05 1997-11-05 Cyclopentylxanthine derivatives for use in the treatment of cystic fibrosis
EP97911336A EP0973521A1 (en) 1996-11-05 1997-11-05 Cyclopentylxanthine derivatives for use in the treatment of cystic fibrosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9622981.0A GB9622981D0 (en) 1996-11-05 1996-11-05 Cystic fibrosis medicaments

Publications (1)

Publication Number Publication Date
GB9622981D0 true GB9622981D0 (en) 1997-01-08

Family

ID=10802439

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9622981.0A Pending GB9622981D0 (en) 1996-11-05 1996-11-05 Cystic fibrosis medicaments

Country Status (5)

Country Link
EP (1) EP0973521A1 (en)
AU (1) AU4875197A (en)
CA (1) CA2270355A1 (en)
GB (1) GB9622981D0 (en)
WO (1) WO1998019679A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2463067A1 (en) * 2001-10-26 2003-05-08 Sciclone Pharmaceuticals, Inc. Pharmaceutical formulations comprising substituted xanthine compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8729714D0 (en) * 1987-12-21 1988-02-03 Lee P F Compositions & method
GB9321083D0 (en) * 1993-10-13 1993-12-01 Univ Mcgill Phosphatase inhibitors in channel diseases

Also Published As

Publication number Publication date
AU4875197A (en) 1998-05-29
EP0973521A1 (en) 2000-01-26
WO1998019679A1 (en) 1998-05-14
CA2270355A1 (en) 1998-05-14

Similar Documents

Publication Publication Date Title
AU1093999A (en) Flavonoids for cystic fibrosis therapy
AU2420797A (en) Novel cystic fibrosis treatment
GB9606805D0 (en) Medicaments
GB9721139D0 (en) Medicaments
AP9700951A0 (en) Medicaments
HUP9901674A3 (en) New pharmaceutical combination
GB9702944D0 (en) Reducing fibrosis
AU7157896A (en) Cystic fibrosis therapy
GB9406573D0 (en) Medicaments
CA85734S (en) Entertainment unit
GB9702021D0 (en) Medicaments
GB9618974D0 (en) Medicaments
GB9718791D0 (en) Medicaments
GB2302048B (en) Rotating nozzle
GB9611947D0 (en) Medicaments
GB9605293D0 (en) Medicaments
EP0991411A4 (en) Treatment for pulmonary fibrosis
GB9622981D0 (en) Cystic fibrosis medicaments
GB9411052D0 (en) Medicaments
GB9611167D0 (en) Medicaments
GB9613096D0 (en) Medicaments
GB9616019D0 (en) Combined medicaments
GB9605329D0 (en) Medicaments
GB9605292D0 (en) Medicaments
GB9600641D0 (en) Medicaments